![](/img/cover-not-exists.png)
Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
John Sweetenham, Klaus Hieke, Matthew Kerrigan, Paul Howard, Pamela F. M. Smartt, Ann-Marie McIntyre, Sarah TownshendVolume:
106
Year:
1999
Language:
english
Pages:
8
DOI:
10.1046/j.1365-2141.1999.01515.x
File:
PDF, 245 KB
english, 1999